Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

NCT01366092 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft-versus-host Disease

Interventions

DRUG: Interleukin-2

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]